{
  "analysis_date": "2025-12-15",
  "validation_summary": {
    "total_cases": 46,
    "correct_predictions": 18,
    "accuracy": "39.1%",
    "average_confidence": "78.6%"
  },
  "tier_performance": {
    "Tier I": {
      "precision": "83.3%",
      "recall": "37.0%",
      "f1_score": "51.3%",
      "issue": "LOW RECALL - missing 17 of 27 Tier I cases (63% miss rate)"
    },
    "Tier II": {
      "precision": "16.0%",
      "recall": "44.4%",
      "issue": "LOW PRECISION - 21 false positives (many Tier I cases incorrectly downgraded to Tier II)"
    },
    "Tier III": {
      "precision": "44.4%",
      "recall": "40.0%",
      "issue": "MODERATE - balanced but still significant errors in both directions"
    }
  },
  "error_categories": {
    "tier_i_to_tier_ii_downgrades": {
      "count": 17,
      "percentage_of_errors": "60.7%",
      "description": "The DOMINANT error pattern - Tier I cases incorrectly classified as Tier II",
      "root_cause": "The prompt says 'later-line restriction ALONE does not downgrade to Tier II if the biomarker-directed therapy IS the guideline-recommended treatment at that line' but LLM is not following this correctly",
      "affected_variants": [
        "BRAF V600E in NSCLC/ATC",
        "KRAS G12C/G12D/G13D in CRC",
        "PIK3CA H1047R/E545K/E542K in Breast Cancer",
        "IDH1 R132H in AML, IDH1 R132C in Cholangiocarcinoma",
        "IDH2 R140Q in AML",
        "KIT D816V/D816H in Systemic Mastocytosis",
        "KIT V560D in GIST",
        "ESR1 Y537S/D538G in Breast Cancer",
        "BRCA1 C61G in Breast Cancer"
      ]
    },
    "tier_ii_to_tier_iii_downgrades": {
      "count": 4,
      "percentage_of_errors": "14.3%",
      "root_cause": "LLM not recognizing resistance markers as Tier II actionable",
      "affected_variants": [
        "EGFR C797S in NSCLC",
        "NRAS Q61K/G12D in Melanoma",
        "MET D1228N in NSCLC"
      ]
    },
    "tier_iii_to_tier_ii_upgrades": {
      "count": 5,
      "percentage_of_errors": "17.9%",
      "root_cause": "Over-weighting sensitivity signals without FDA biomarker requirements",
      "affected_variants": [
        "BRAF G469A in Melanoma",
        "TP53 R175H in CRC",
        "APC R1450* in CRC",
        "VHL R167Q in ccRCC",
        "SMAD4 R361H in Pancreatic Cancer"
      ]
    },
    "other_errors": {
      "count": 2,
      "cases": [
        "KRAS G12D in Pancreatic Cancer: Tier III ’ Tier I (hallucinated FDA approval)",
        "KIT D816V in GIST: Tier II ’ Tier I (context-dependent - D816V is resistance in GIST)"
      ]
    }
  },
  "key_insights": {
    "main_problem": "The 'later-line' logic is too aggressive - downgrading Tier I cases to Tier II when the biomarker-directed therapy IS the standard-of-care at that treatment line",
    "evidence": "17 of 28 errors (60.7%) are Tier I to Tier II downgrades citing 'later-line treatment'",
    "pattern": "LLM sees 'after prior therapy' in FDA label and auto-downgrades to Tier II, ignoring that this IS the standard approach for these biomarkers"
  },
  "proposed_fixes": [
    {
      "priority": 1,
      "description": "Add explicit biomarker+tumor combinations where later-line therapy IS the standard (Tier I)",
      "examples": [
        "BRAF V600E/K + NSCLC: dabrafenib+trametinib = Tier I",
        "BRAF V600E + ATC: dabrafenib+trametinib = Tier I",
        "PIK3CA hotspots + HR+/HER2- breast: alpelisib = Tier I",
        "IDH1/2 mutations + AML: ivosidenib/enasidenib = Tier I",
        "ESR1 mutations + ER+ breast: elacestrant = Tier I",
        "KIT exon 11 + GIST: imatinib = Tier I",
        "KIT D816V + SM: midostaurin/avapritinib = Tier I",
        "KRAS G12C + CRC: sotorasib = Tier I"
      ],
      "estimated_impact": "Would fix ~17 errors (60.7%)"
    },
    {
      "priority": 2,
      "description": "Clarify that RAS mutations in CRC are Tier I resistance markers (NCCN mandated testing)",
      "rationale": "KRAS/NRAS mutations in CRC exclude anti-EGFR therapy - this is Tier I because it's NCCN Category 1 mandated testing",
      "estimated_impact": "Would fix ~3 KRAS CRC errors"
    },
    {
      "priority": 3,
      "description": "Add negative list of genes that are NOT therapeutically targetable",
      "examples": ["TP53", "APC", "VHL (in ccRCC)", "SMAD4"],
      "estimated_impact": "Would fix ~5 over-upgraded errors"
    }
  ]
}
